selecta biosciences clinical trial

DISSOLVE I will access efficacy, as measured by serum uric acid levels at 6 months, with a 6 month extension to evaluate safety. Selecta plans to combine ImmTOR with a range of biologic therapies for rare and serious diseases that require new treatment options due to high immunogenicity. After the company reported its gout drug, SEL-212, failed to meet its primary endpoint in a mid-stage clinical trial, shares in Selecta Biosciences (NASDAQ:SELB) traded 33.5% lower … STOCKHOLM, Sweden and WATERTOWN, Mass., Sept. 23, 2020 (GLOBE NEWSWIRE) -- Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) and Selecta Biosciences, Inc. (Nasdaq: SELB) today announced the commencement of the phase 3 clinical program of SEL-212 for chronic refractory gout, with the randomization of the first patient in the study. By Mark Terry . Selecta Biosciences and AskBio Initiate First-in-Human Dose-Escalation Study to Evaluate ImmTOR™ in Gene Therapy - Clinical trial commences in … About Selecta Biosciences, Inc. Selecta Biosciences, Inc. is a clinical-stage biotechnology company focused on unlocking the full potential of … Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company developing a novel class of targeted antigen-specific immune therapies, today announced the dosing of the first patient in the Company’s Phase 1b clinical trial to assess the safety, pharmacodynamic profile and efficacy of SEL-212, Selecta’s proprietary biologic treatment for refractory and tophaceous gout. About Selecta Biosciences, Inc. Selecta Biosciences Inc. (NASDAQ: SELB) is leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses. Selecta Biosciences, a clinical-stage biopharmaceutical company, and the National Cancer Institute (NCI) teamed up for the phase 1 clinical trial under the Cooperative Research and Development Agreement. Selecta Biosciences Inc. (NASDAQ: SELB) is a clinical stage biotechnology company leveraging its ImmTOR™ platform to develop tolerogenic … The trial consists of two double-blinded, placebo-controlled studies, DISSOLVE I and DISSOLVE II. Selecta Biosciences intends to raise $50m through private placement of shares of its common stock to be subscribed to by new and existing institutional investors and one of the company’s board of directors.. WATERTOWN, Mass., May 11, 2017 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB) today announced that patient dosing has commenced in a Phase 1 clinical trial to assess the safety, tolerability and pharmacodynamic profile of SELA-070, a nicotine vaccine candidate in development for smoking cessation and relapse prevention. Selecta Biosciences, Inc. (SELB), a clinical … Selecta Biosciences Initiates Head-to-Head Clinical Trial (COMPARE) of SEL-212 vs. KRYSTEXXA® in Patients with Chronic March 29, 2019, 8:00 AM EDT SHARE THIS ARTICLE Selecta Biosciences’ New CEO Restructures, Cuts 36% of Staff . Selecta Biosciences and AskBio Initiate First-in-Human Dose-Escalation Study to Evaluate ImmTOR in Gene Therapy – Clinical trial commences in healthy adult volunteers to … Selecta Biosciences is developing SEL-212 as a treatment in chronic refractory gout. About Methylmalonic Acidemia Methylmalonic acidemia (MMA) is a … The Manager, Clinical Operations is a pivotal member of Selecta's clinical team. The Manager, Clinical Operations is a pivotal member of Selecta's clinical team. The AAV gene therapy involves creating viral vectors for treating diseases. “We are pleased to have … Selecta Biosciences, Inc. is a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance technology (ImmTOR) platform. Selecta Biosciences, based in Watertown, Mass., announced that as part of restructuring efforts it is cutting its current workforce by 36 percent.. The average salary for Clinical Trials Data Analyst II at companies like SELECTA BIOSCIENCES INC in the United States is $77,630 as of January 29, 2021, but the range typically falls between $66,380 and $91,410. ADVERTISEMENT The FDA Office of Orphan Products Development grants orphan drug designation to investigational treatments intended for rare diseases affecting fewer than 200,000 people in the U.S. Selecta Biosciences Inc. (NASDAQ: SELB) is a clinical stage biotechnology company leveraging its ImmTOR platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses. Selecta Biosciences, Inc. is a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance technology (ImmTOR) platform. About Selecta Biosciences, Inc. Selecta Biosciences Inc. ( SELB) is a clinical stage biotechnology company leveraging its ImmTORâ ¢ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses. Selecta Biosciences, Inc. is a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance (ImmTOR) platform. Selecta and AskBio expect to report initial results from this clinical trial in the fourth quarter of 2021. SEL-313 is currently in preclinical development and a clinical trial application, or CTA and/or IND filing are expected in 2022. WATERTOWN, Mass., April 29, 2021 (News) — Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced three upcoming presentations at the 24th Annual Meeting of the American Society of Gene & Cell Therapy … AskBio and Selecta expect to initiate a Phase 1 clinical trial of MMA-101 and ImmTOR for patients with MMA in the first half of 2021. Selecta Biosciences expects to commence a clinical trial of ImmTOR in gene therapy in 2020. The trial is … Selecta Biosciences, Inc. (“the company”), including without limitation, the company’s actions regarding the monitoring and assessment of COVID-19 on the company’s operations, clinical trials and manufacturing, Sarepta’s plans to evaluate its gene therapies in combination with the company’s ImmTOR technology, the possibility of Sarepta exercising an option to enter into a … SEL-212 is currently being evaluated in a Phase 3 clinical trial being run by Selecta on behalf of Sobi. Selecta Biosciences is a clinical-stage biotechnology company with an unrelenting commitment to overcoming immunogenicity with our pioneering ImmTOR™ immune tolerance platform. Our clinically validated ImmTOR™ platform allows us to develop tolerogenic therapies that selectively mitigate unwanted immune responses. Selecta Biosciences Announces Completion of Enrollment in Head-to-Head COMPARE Trial of SEL-212. jan 8 (reuters) - selecta biosciences inc: * selecta biosciences says expects to report initial results for phase 2 clinical trial of sel-212 in chronic severe gout in april 2018 - sec filing Selecta plans to explore the potential of re-dosing AAV gene therapy: Their proprietary product platform technology combines recent advances in immunobiology with cutting-edge nanotechnology to develop targeted immunomodulatory nanoparticles. Selecta Biosciences, Inc. announced the dosing of the first patient in the Company’s Phase 1b clinical trial of SEL-212, Selecta’s proprie About Selecta Biosciences, Inc. ... AskBio’s collaboration with Selecta and AskBio’s clinical trials, including the SEL-399 trial, and manufacturing technology and process. Selecta Biosciences is a clinical-stage biotechnology company with an unrelenting commitment to overcoming immunogenicity with our pioneering ImmTOR™ immune tolerance platform. Selecta Biosciences, Inc. (NASDAQ:SELB) today announced that patient dosing has commenced in a Phase 1 clinical trial to assess the safety, tolerability and pharmacodynamic profile of SELA-070, a nicotine vaccine candidate in development for smoking cessation and relapse prevention. Science Overall % chance of successful phase 1, 2, or 3, based on bio.org clinical development… About Selecta Biosciences, Inc. Selecta Biosciences Inc. (NASDAQ: SELB) is a clinical stage biotechnology company leveraging its ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses. First Immunotherapeutic Candidate to Leverage Selecta’s Proprietary Synthetic Vaccine Particle PlatformSEL-212 Targeting Unmet Needs of Chronic Refractory and Tophaceous Gout PatientsInitial... | April 4, 2021 Selecta Biosciences, Inc. is a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its pioneering immune tolerance platform (ImmTOR™). With a proven ability to induce tolerance to highly immunogenic … About Selecta Biosciences, Inc. Selecta Biosciences Inc. (NASDAQ: SELB) is a clinical stage biotechnology company leveraging its ImmTOR platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses. Selecta Biosciences Reports First Quarter 2020 Financial Results. The trial enrolled 150 patients across 49 sites trial and is evaluating the superiority of a once-monthly dose of Selecta’s lead product candidate, SEL-212 (ImmTOR + … WATERTOWN, Mass., Oct. 26, 2016 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB), a clinical-stage biopharmaceutical company developing a novel class of targeted antigen-specific immune therapies, today announced that it has dosed the first patient in its Phase 2 clinical trial of SEL-212, the company’s lead proprietary immunotherapeutic product candidate for the … Selecta Biosciences Reports First Quarter 2021 Financial Results and Provides Business Update. March 30, 2021. Selecta and AskBio expect to report initial results from this clinical trial in the fourth quarter of 2021. Selecta Biosciences, Inc. ClinicalTrials.gov Identifier: NCT03905512 Other Study ID Numbers: SEL-212/202 : First Posted: April 5, 2019 Key Record Dates: Last Update Posted: September 22, 2020 Last Verified: September 2020 Individual Participant Data (IPD) Sharing Statement: Plan to … Selecta Biosciences, Inc. (NASDAQ: SELB) and Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI), today announced topline data for the Phase 2 COMPARE trial comparing the efficacy of SEL-212, a combination of Selecta's ImmTOR™ immune tolerance platform and a therapeutic uricase enzyme (pegadricase), to pegloticase (KRYSTEXXA®), the currently approved uricase in the … Selecta and AskBio expect to report initial results from this clinical trial in the fourth quarter of 2021. Results are expected soon and Selecta has planned a Phase 2 trial if data is positive. PRINCIPAL DUTIES/RESPONSIBILITIES Manage and track on an ongoing basis the overall program data from … Selecta plans to combine ImmTOR with a range of biologic therapies for rare and serious diseases that require new treatment options due to high immunogenicity. Selecta Biosciences is a biopharmaceutical company developing the first generation of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Clinical Trial Associate jobs ... Selecta Biosciences | 1,281 followers on LinkedIn. Senior Clinical Data Analyst SUMMARY The Senior Clinical Data Analyst is responsible for the oversight of all study-related data for Selecta's clinical studies, the management, tracking and analysis of the data, and for preparing presentations of and/or presenting the data. Selecta Biosciences, Inc. is a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance technology (ImmTOR) platform. A clinical trial testing a new therapeutic modality on patients with pleural and peritoneal mesothelioma is officially underway. AskBio and Selecta expect to initiate a Phase 1 clinical trial of MMA-101 and ImmTOR for patients with MMA in 1H 2021. Selecta Biosciences is helping power the efficacy of cutting-edge biological treatments. ImmTOR powers sustained efficacy of pegadricase for chronic refractory gout, a debilitating disease that affects approximately 160,000 people in the United States. SELB – Selecta Biosciences, Inc. - Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company using its proprietary synthetic vaccine particle technology to discover & develop targeted therapies designed to modulate the immune system to treat rare and serious diseases. AboutSelecta Biosciences, Inc.Selecta Biosciences Inc. (NASDAQ: SELB) is leveraging its clinically validated ImmTOR platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses. Selecta Biosciences, Inc. is a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance (ImmTOR) platform. Selecta and AskBio expect to report initial results from this clinical trial in the fourth quarter of 2021. Selecta Applies SVP™ Technology for Immune Stimulation to Address Significant Public Health Issue Program Being Funded Primarily by U.S. National Institutes The drug candidate is expected to begin a phase 3 clinical trial in the second half of 2020. Selecta and AskBio expect to report initial results from this clinical trial in the fourth quarter of 2021. Selecta Biosciences Combines ImmTOR™ Platform with AskBio’s Industry-Leading Gene Therapy Platform in Strategic Partnership filed by Selecta Biosciences Inc on August 7th, 2019. However, Selecta changed its plans after getting a look at data from a phase 2 trial of SEL-212 in October. Selecta Biosciences, Inc. is a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance technology (ImmTOR) platform. Selecta Biosciences is developing SEL-212 as a treatment in chronic refractory gout. Selecta Biosciences Inc. (NASDAQ: SELB) is leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses. The company believes that the cuts, along with a reprioritization of its pipeline, will decrease its yearly cash burn by 19 percent. As CFO of Selecta Biosciences from 2009 to 2017, he also built the finance and accounting organization, and led the company to a successful IPO in June 2016. Developing selective tolerogenic therapies and restoring self-tolerance in autoimmune diseases. Selecta Biosciences is a clinical-stage biotechnology company with an unrelenting commitment to overcoming immunogenicity with our pioneering ImmTOR™ immune tolerance platform. About Selecta Biosciences, Inc. Selecta Biosciences Inc. (NASDAQ: SELB) is leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses. SGS Facilitates Selecta Biosciences and AskBio’s FIH Study to Evaluate ImmTOR™ in Gene Therapy. About Selecta Biosciences, Inc. Selecta Biosciences Inc. (NASDAQ: SELB) is leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses. --Selecta Biosciences, Inc., a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune … Selecta Biosciences Reports Fourth Quarter 2019 and Year-End Financial Results, Stocks: SELB, release date:Mar 12, 2020 Selecta Biosciences, Inc. (NASDAQ:SELB) Q4 2020 Earnings Conference Call March 11, 2021, 08:30 AM ET Company Participants Brad Dahms - CFO Carsten Brunn - … The average hourly wage for a Clinical Trials Data Analyst II at companies like SELECTA BIOSCIENCES INC in the United States is $37 as of February 26, 2021, but the range typically falls between $32 and $44. Selecta Biosciences’ New CEO Restructures, Cuts 36% of Staff . Selecta Biosciences, based in Watertown, Mass., announced that as part of restructuring efforts it is cutting its current workforce by 36 percent.. DISSOLVE II will access efficacy as measured by serum uric acid levels … About Selecta Biosciences, Inc. Selecta Biosciences Inc. (SELB) is leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses. The results of the planned head-to-head superiority trial are expected to inform the design of the planned Phase 3 clinical trial of SEL-212, which the company plans to initiate in the fourth quarter of 2019. WATERTOWN, Mass., and Research Triangle Park, N.C., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB) and Asklepios BioPharmaceutical, Inc. (AskBio), today announced the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation to MMA-101 for the treatment of isolated methylmalonic acidemia (MMA) due to … Browse A-Z; Browse by Tag: Contract Type Country Jurisdiction Industry Company Person Law Firm Filing ID SEC Filing Type SEC Exhibit ID. Selecta and Sobi recently announced the initiation of two double-blinded, placebo-controlled Phase 3 clinical trials (DISSOLVE I and DISSOLVE II) … Selecta Biosciences, Inc. ... We expect to file the IND for MMA-101 in the first quarter of 2021, and commence the Phase 1 clinical trial for this product candidate in the first half of 2021. WATERTOWN, Mass., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB, “Selecta”), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced the peer-reviewed publication of a study investigating the effects of the co-administration … Selecta plans to combine ImmTOR with a range of biologic therapies for rare and serious diseases that require new treatment options due to high immunogenicity. Selecta Biosciences Announces Dosing of First Patient in Phase 1b Clinical Trial of SEL-212, Designed to be the First Non-Immunogenic Biologic Treatment for Gout 12.23.2015; Selecta Continues to Successfully Advance Pipeline of Novel Immunotherapeutic Candidates 10.16.2015; Selecta Announces $38 Million Series E Financing 09.08.2015 ... A phase II trial … Leveraging clinically validated ImmTOR™ platform to develop tolerogenic therapies. About Selecta Biosciences, Inc. Selecta Biosciences Inc. (NASDAQ: SELB) is leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses. The project is being funded primarily by … WATERTOWN, Mass., Nov. 01, 2019 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform technology, ImmTOR™, today announced that it plans to issue its third quarter 2019 financial results on Friday November 8, 2019. Contracts. In December last year, Selecta began dosing for a Phase 1b trial of its lead candidate, a biologic gout treatment known as SEL-212. By Mark Terry . Selecta Biosciences, Inc. is a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its pioneering immune tolerance platform (ImmTOR™). Selecta plans to combine ImmTOR with a range of biologic therapies for rare and serious diseases that require new treatment options due to high immunogenicity. The drug candidate is expected to begin a phase 3 clinical trial in the second half of 2020. WATERTOWN, Mass., June 06, 2017 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies by avoiding unwanted immune responses, today announced the following upcoming clinical presentations: Annual European Congress of Rheumatology (EULAR 2017) Title: SEL-212: … About Selecta Biosciences, Inc. Selecta Biosciences Inc. (NASDAQ: SELB) is a clinical stage biotechnology company leveraging its ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses. Selecta Biosciences is a clinical-stage biotechnology company developing biologic therapies based on its immune tolerance technology (ImmTOR) platform. Our Platform ImmTOR TM Selective Immune Tolerance Technology A Phase 1a trial showed some efficacy in reducing uric acid levels in patients. So what. Selecta Biosciences, Inc. recently announced it has dosed the first patient in its Phase II clinical trial of SEL-212, the company’s lead proprietary immunotherapeutic product candidate for the treatment of chronic gout in patients refractory to conventional therapy. Selecta and AskBio expect to report initial results from this clinical trial in the fourth quarter of 2021. Topline Results from COMPARE Clinical Trial Expected in the Third Quarter of 2020: The head-to-head COMPARE study of Selecta’s lead product candidate, SEL-212 (ImmTOR + pegadricase), vs. pegloticase is expected to readout on schedule, as the Company continues to work closely with the CRO and clinical sites to monitor patient follow-up in light of the COVID-19 pandemic. The company believes that the cuts, along with a reprioritization of its pipeline, will decrease its yearly cash burn by 19 percent. Manager, Clinical Operations Selecta Biosciences, Inc. is a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance (ImmTOR) platform. Selecta Biosciences Announces Dosing of First Patient in Phase 1b Clinical Trial of SEL-212, Designed to be the First Non-Immunogenic Biologic Treatment for Gout 12.23.2015; Selecta Continues to Successfully Advance Pipeline of Novel Immunotherapeutic Candidates 10.16.2015; Selecta Announces $38 Million Series E Financing 09.08.2015

Stafford, Ct Real Estate, Monoprix Qatar Customer Service, Chilobrachys Sp Kaeng Krachan, Fleshgod Apocalypse Religion, Las Vegas Wedding Packages All-inclusive With Hotel, Pitt Women's Soccer Schedule 2021, Lube Technician Requirements,